Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial
ConclusionsThe combination of belinostat 2000 mg/m2 days 1 –5 and 13-cRA 100 mg/m2 days 1 –14, every 21 days, was well-tolerated and an MTD was not reached despite doubling the established single-agent MTD of belinostat.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Brain | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Drugs & Pharmacology | Hematology | Hepatocellular Carcinoma | Liver | Liver Cancer | Lung Cancer | Neurology | Pancreas | Pancreatic Cancer | Skin Cancer | Squamous Cell Carcinoma | Study | Tonsillitis | Toxicology | Urology & Nephrology